References

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

10.1056/nejmoa043330 · 2005 · External reference

20 years of the stupp protocol: confronting stagnation in glioblastoma therapy

10.1016/s1470-2045(25)00705-3 · 2026 · External reference

Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review

10.1016/j.adro.2019.03.009 · 2019 · External reference

Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen, Childrens Cancer Group

10.1200/jco.1995.13.1.112 · 1995 · External reference

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the children’s oncology group

10.1093/neuonc/noq205 · 2011 · External reference

An integrative model of cellular states, plasticity, and genetics for glioblastoma

10.1016/j.cell.2019.06.024 · 2019 · External reference

Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective

10.1016/j.cell.2023.12.013 · 2024 · External reference

Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas

10.1038/s41467-023-36707-6 · 2023 · External reference

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

10.1038/s41588-022-01236-3 · 2022 · External reference

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

10.1016/j.ccell.2024.08.006 · 2024 · External reference

Quantitative analysis of immune cells within the tumor microenvironment of glioblastoma and their relevance for prognosis

2024 · External reference

Tumor microenvironment in glioblastoma: the central role of the hypoxic–necrotic core

10.1016/j.canlet.2025.218216 · 2026 · External reference

Immune microenvironment in glioblastoma subtypes

10.3389/fimmu.2018.01004 · 2018 · External reference

Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization

10.1016/j.ccell.2024.03.013 · 2024 · External reference

The multifaceted role of perivascular macrophages in tumors

10.1016/j.ccell.2016.05.017 · 2016 · External reference

Microglia and brain macrophages are differentially associated with tumor necrosis in glioblastoma: a link to tumor progression

10.32604/or.2024.056436 · 2025 · External reference

Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion

10.1016/j.immuni.2024.11.026 · 2025 · External reference

CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients

10.1093/neuonc/nov280 · 2016 · External reference

CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells

10.1158/0008-5472.can-16-0144 · 2016 · External reference

Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway

10.1186/s12951-024-02888-5 · 2024 · External reference

Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages

10.1186/s12964-024-01523-y · 2024 · External reference

Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner

10.1152/ajpcell.00124.2024 · 2024 · External reference

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma

10.1186/s40478-018-0553-x · 2018 · External reference

IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma

10.1016/j.ccell.2025.12.020 · 2026 · External reference

Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations

10.1016/j.immuni.2024.09.007 · 2024 · External reference

Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function

10.1038/s41467-024-52096-w · 2024 · External reference

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma

10.1016/j.ccell.2021.05.002 · 2021 · External reference

The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: a systematic review

2024 · External reference

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma

10.1038/s41591-025-03512-1 · 2025 · External reference

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

10.1186/s13046-019-1085-3 · 2019 · External reference

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

10.1093/neuonc/nop020 · 2010 · External reference

NRG-BN002: phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma

10.1093/neuonc/noae058 · 2024 · External reference

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: a novel combinatorial immunotherapy regimen for gliomas

10.1093/neuonc/noae135 · 2024 · External reference

Unresolved reference

External reference

TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma

10.3389/fimmu.2021.637146 · 2021 · External reference

Immunosuppressive tumor microenvironment and therapeutic landscape of diffuse intrinsic pontine glioma

10.1002/med.70037 · 2026 · External reference

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

10.1172/jci.insight.175257 · 2024 · External reference

Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma

10.1093/neuonc/noaf039 · 2025 · External reference

Unresolved reference

External reference

Insights into the leveraging of GABAergic signaling in cancer therapy

10.1002/cam4.6102 · 2023 · External reference

Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression

10.1038/s41556-021-00820-9 · 2022 · External reference

B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity

10.1038/s41586-021-04082-1 · 2021 · External reference

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

10.1073/pnas.87.11.4207 · 1990 · External reference

A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors

10.1111/j.1349-7006.1990.tb02644.x · 1990 · External reference

Structural alterations of the epidermal growth factor receptor gene in human gliomas

10.1073/pnas.89.7.2965 · 1992 · External reference

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

10.1073/pnas.91.16.7727 · 1994 · External reference

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients

10.1158/1078-0432.ccr-04-1737 · 2005 · External reference

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

10.1016/s1470-2045(17)30517-x · 2017 · External reference

Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-Expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial

10.1158/1078-0432.ccr-18-1140 · 2020 · External reference

Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

10.1084/jem.20111424 · 2012 · External reference

Vascular endothelial growth factor (VEGF) signaling in tumor progression

10.1016/j.critrevonc.2007.01.006 · 2007 · External reference

VEGF targets the tumour cell

10.1038/nrc3627 · 2013 · External reference

A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma

10.18632/oncotarget.25131 · 2018 · External reference

Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

10.1186/s12885-020-6589-x · 2020 · External reference

Expression of WT1 protein and correlation with cellular proliferation in glial tumors

10.2176/nmc.47.165 · 2007 · External reference

Induction of WT1 (wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

10.1073/pnas.0405884101 · 2004 · External reference

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

10.3171/jns/2008/108/5/0963 · 2008 · External reference

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

10.1038/nm0897-917 · 1997 · External reference

Quantitatively determined survivin expression levels are of prognostic value in human gliomas

10.1200/jco.2002.20.4.1063 · 2002 · External reference

Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis

10.1002/cncr.11122 · 2003 · External reference

Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

10.1007/s00262-010-0845-x · 2010 · External reference

Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma

10.1200/jco.22.00996 · 2023 · External reference

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

10.1172/jci140378 · 2020 · External reference

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma

10.1136/jitc-2022-005535 · 2022 · External reference

A H3K27M-targeted vaccine in adults with diffuse midline glioma

10.1038/s41591-023-02555-6 · 2023 · External reference

IDH1 and IDH2 mutations in gliomas

10.1056/nejmoa0808710 · 2009 · External reference

A vaccine targeting mutant IDH1 in newly diagnosed glioma

10.1038/s41586-021-03363-z · 2021 · External reference

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

10.1093/brain/aws042 · 2012 · External reference

A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma

10.1158/1078-0432.ccr-16-0506 · 2016 · External reference

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

10.1093/neuonc/noz040 · 2019 · External reference

Autologous formalin-fixed tumor vaccine

10.2174/1381612053507620 · 2005 · External reference

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma: clinical article

10.3171/2014.5.jns132392 · 2014 · External reference

A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas

10.3171/2022.12.jns221221 · 2023 · External reference

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas

10.1200/jco.2001.19.8.2189 · 2001 · External reference

Phase 1 trial of vaccination with autologous tumor cells and antisense directed against the insulin growth factor type 1 receptor (IGF-1R AS ODN) in patients with recurrent glioblastoma

10.29046/jhnj.013.1.002 · 2018 · External reference

Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma

10.1158/1078-0432.ccr-20-3805 · 2021 · External reference

Use of ERC-1671 vaccine in a patient with recurrent glioblastoma multiforme after progression during bevacizumab therapy: first published report

10.7812/tpp/14-042 · 2015 · External reference

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

10.1007/s11060-016-2245-3 · 2016 · External reference

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

10.2217/cns-2018-0009 · 2018 · External reference

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

10.1038/s41467-024-51315-8 · 2024 · External reference

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

10.1038/s41586-018-0792-9 · 2019 · External reference

Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial

10.1001/jamaoncol.2022.5370 · 2023 · External reference

Antigen-specific T-Cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens

10.1002/stem.102 · 2009 · External reference

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

10.1007/s00262-012-1319-0 · 2013 · External reference

RNA aggregates harness the danger response for potent cancer immunotherapy

10.1016/j.cell.2024.04.003 · 2024 · External reference

Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors

10.1136/jitc-2025-011817 · 2025 · External reference